Literature DB >> 12579299

Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

Fumin Chang1, Linda S Steelman, John G Shelton, John T Lee, Patrick M Navolanic, William L Blalock, Richard Franklin, James A McCubrey.   

Abstract

The Ras/Raf/MEK/ERK signal transduction pathway regulates cell cycle progression and apoptosis in diverse types of cells. Mutations in this pathway are often observed in transformed cell lines and frequently linked with human cancers. The Ras/Raf/MEK/ERK pathway can induce events both associated with cell proliferation and cell cycle arrest. The particular course chosen may depend on the strength and the particular Raf gene activated by Ras. This pathway also is involved in maintaining cell survival by modulating the activity of apoptotic molecules including Bad and Bcl-2. This review will discuss the regulation of the Ras/Raf/MEK/ERK pathway and how it modulates cell cycle progression and cell survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579299

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  111 in total

1.  ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression.

Authors:  Lionel Le Gallic; Laura Virgilio; Philip Cohen; Benoit Biteau; George Mavrothalassitis
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

2.  A global genomic view on LNX siRNA-mediated cell cycle arrest.

Authors:  Dan Zheng; Shaohua Gu; Yao Li; Chaoneng Ji; Yi Xie; Yumin Mao
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

3.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

4.  Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice.

Authors:  Huimin Zhang; William E Lawson; Vasiliy V Polosukhin; Ambra Pozzi; Timothy S Blackwell; Ying Litingtung; Chin Chiang
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 5.  Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.

Authors:  Claudia Trojaniello; Jason J Luke; Paolo A Ascierto
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

6.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.

Authors:  Nathan J Schuld; Andrew D Hauser; Adam J Gastonguay; Jessica M Wilson; Ellen L Lorimer; Carol L Williams
Journal:  Cell Cycle       Date:  2014-01-16       Impact factor: 4.534

8.  Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia.

Authors:  Hanako Sato; Takuya Yazawa; Takehisa Suzuki; Hiroaki Shimoyamada; Koji Okudela; Masaichi Ikeda; Kenji Hamada; Hisafumi Yamada-Okabe; Masayuki Yao; Yoshinobu Kubota; Takashi Takahashi; Hiroshi Kamma; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

9.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.